FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:395-397 July 24, 2003 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Sinha, A. PubMed Citation

The treatment of active ulcerative colitis largely relies on the nonspecific antiinflammatory effects of aminosalicylates (mesalamine and sulfasalazine) and the broad immunosuppressive actions of corticosteroids and other potent immunomodulators.¹ Data from animal models and patients with ulcerative colitis have highlighted the importance of the enteric microflora in the pathogenesis of the disease, yet in clinical trials, antibiotics and probiotics have had only limited efficacy against active disease. In ulcerative colitis, in contrast to Crohn's disease, there are few clinical data on the value of infliximab and other biologic agents.

The pathogenesis of ulcerative colitis remains unknown, but the disease may . . . [Full Text of this Article]

Source Information

From the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston.

This article has been cited by other articles:

• O'Mahony, F., Toumi, F., Mroz, M. S., Ferguson, G., Keely, S. J. (2008). Induction of Na+/K+/2Cl- cotransporter expression mediates chronic potentiation of intestinal epithelial Cl- secretion by EGF. Am. J. Physiol. Cell Physiol. 294: C1362-C1370 [Abstract] [Full Text]